• Je něco špatně v tomto záznamu ?

Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT)

R. Kočková, K. Sedláček, D. Wichterle, V. Šikula, J. Tintěra, H. Jansová, A. Pravečková, R. Langová, L. Krýže, W. El-Husseini, M. Segeťová, J. Kautzner,

. 2018 ; 270 (-) : 325-330. [pub] 20180606

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012612

BACKGROUND: Cardiac resynchronization therapy (CRT) improves symptoms of heart failure (HF), morbidity and mortality in selected population. The aim of the study was to investigate the impact of cardiac magnetic resonance (CMR)-guided left ventricular (LV) lead placement on clinical outcomes and LV reverse remodelling in CRT recipients. METHODS: Patients with CRT indication were randomized for CMR-guided (CMR group) or electrophysiologically guided (EP group) LV lead placement between 2011 and 2014. The target site in the CMR group was defined as the most delayed, scar-free, in the EP group as the site with the longest interval between the QRS onset and local electrogram. The primary endpoint was a combination of cardiovascular death or HF hospitalization. Secondary endpoints were New York Heart Association (NYHA) Class improvement ≥1, LV endsystolic diameter reduction >10%, B-type natriuretic peptide reduction by ≥30%. RESULTS: A total of 99 patients (47 in the CMR and 52 in the EP group) were enrolled. During a median follow-up of 47 months, primary composite endpoint occurred in 5 patients in the CMR group and 14 patients in the EP group (HR = 0.46; 95% CI: 0.16-1.32). Patients with left bundle branch block and NYHA Class >2 had better clinical outcome in the CMR group (HR = 0.09; 95% CI: 0.01-0.75). CONCLUSIONS: The use of CMR did not result in significant reduction of combined endpoint of cardiovascular death or HF hospitalization in the total study population. Significant clinical benefit from CMR-guided procedure was observed in a subgroup of optimum CRT candidates with advanced HF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012612
003      
CZ-PrNML
005      
20211229141909.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2018.06.009 $2 doi
035    __
$a (PubMed)29908832
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kočková, Radka $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic; Charles University, Faculty of Medicine in Hradec Králové, Šimkova 870, Hradec Králové 500 03, Czech Republic. Electronic address: radka.kockova@ikem.cz.
245    10
$a Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT) / $c R. Kočková, K. Sedláček, D. Wichterle, V. Šikula, J. Tintěra, H. Jansová, A. Pravečková, R. Langová, L. Krýže, W. El-Husseini, M. Segeťová, J. Kautzner,
520    9_
$a BACKGROUND: Cardiac resynchronization therapy (CRT) improves symptoms of heart failure (HF), morbidity and mortality in selected population. The aim of the study was to investigate the impact of cardiac magnetic resonance (CMR)-guided left ventricular (LV) lead placement on clinical outcomes and LV reverse remodelling in CRT recipients. METHODS: Patients with CRT indication were randomized for CMR-guided (CMR group) or electrophysiologically guided (EP group) LV lead placement between 2011 and 2014. The target site in the CMR group was defined as the most delayed, scar-free, in the EP group as the site with the longest interval between the QRS onset and local electrogram. The primary endpoint was a combination of cardiovascular death or HF hospitalization. Secondary endpoints were New York Heart Association (NYHA) Class improvement ≥1, LV endsystolic diameter reduction >10%, B-type natriuretic peptide reduction by ≥30%. RESULTS: A total of 99 patients (47 in the CMR and 52 in the EP group) were enrolled. During a median follow-up of 47 months, primary composite endpoint occurred in 5 patients in the CMR group and 14 patients in the EP group (HR = 0.46; 95% CI: 0.16-1.32). Patients with left bundle branch block and NYHA Class >2 had better clinical outcome in the CMR group (HR = 0.09; 95% CI: 0.01-0.75). CONCLUSIONS: The use of CMR did not result in significant reduction of combined endpoint of cardiovascular death or HF hospitalization in the total study population. Significant clinical benefit from CMR-guided procedure was observed in a subgroup of optimum CRT candidates with advanced HF.
650    _2
$a senioři $7 D000368
650    _2
$a srdeční resynchronizační terapie $x metody $7 D058406
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a srdeční selhání $x diagnostické zobrazování $x patofyziologie $x terapie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonance kinematografická $x metody $7 D019028
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Sedláček, Kamil $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Wichterle, Dan $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic; Charles University, First Faculty of Medicine, Kateřinská 32, Praha 121 08, Czech Republic.
700    1_
$a Šikula, Viktor $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Tintěra, Jaroslav $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Jansová, Helena $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Pravečková, Alena $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Langová, Renata $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Krýže, Lukáš $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic. $7 xx0267909
700    1_
$a El-Husseini, Wael $7 xx0245083 $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Segeťová, Markéta $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
700    1_
$a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 270, č. - (2018), s. 325-330
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29908832 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20211229141906 $b ABA008
999    __
$a ok $b bmc $g 1391922 $s 1050917
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 270 $c - $d 325-330 $e 20180606 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace